Patents Assigned to Enterprises of Kings College London Capital House
  • Publication number: 20060029544
    Abstract: The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a pi-pi stacking moiety conjugated to its ?-amino group. Methods for identifying receptor-binding cyclic peptides and for using the cyclic peptides of the present invention for imaging a tumor, organ, or tissue and for treating cancer, inflammatory diseases, and autoimmune diseases are also provided.
    Type: Application
    Filed: August 5, 2005
    Publication date: February 9, 2006
    Applicants: The Regents of the University of California Office of Technology Transfer, Cancer Research Technology Ltd., Enterprises of Kings College London Capital House
    Inventors: Julie Sutcliffe-Goulden, John Marshall, Mark Howard, Michael O'Doherty